» Articles » PMID: 21606442

Lung Cancer Risk Prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial Models and Validation

Overview
Specialty Oncology
Date 2011 May 25
PMID 21606442
Citations 130
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Identification of individuals at high risk for lung cancer should be of value to individuals, patients, clinicians, and researchers. Existing prediction models have only modest capabilities to classify persons at risk accurately.

Methods: Prospective data from 70 962 control subjects in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) were used in models for the general population (model 1) and for a subcohort of ever-smokers (N = 38 254) (model 2). Both models included age, socioeconomic status (education), body mass index, family history of lung cancer, chronic obstructive pulmonary disease, recent chest x-ray, smoking status (never, former, or current), pack-years smoked, and smoking duration. Model 2 also included smoking quit-time (time in years since ever-smokers permanently quit smoking). External validation was performed with 44 223 PLCO intervention arm participants who completed a supplemental questionnaire and were subsequently followed. Known available risk factors were included in logistic regression models. Bootstrap optimism-corrected estimates of predictive performance were calculated (internal validation). Nonlinear relationships for age, pack-years smoked, smoking duration, and quit-time were modeled using restricted cubic splines. All reported P values are two-sided.

Results: During follow-up (median 9.2 years) of the control arm subjects, 1040 lung cancers occurred. During follow-up of the external validation sample (median 3.0 years), 213 lung cancers occurred. For models 1 and 2, bootstrap optimism-corrected receiver operator characteristic area under the curves were 0.857 and 0.805, and calibration slopes (model-predicted probabilities vs observed probabilities) were 0.987 and 0.979, respectively. In the external validation sample, models 1 and 2 had area under the curves of 0.841 and 0.784, respectively. These models had high discrimination in women, men, whites, and nonwhites.

Conclusion: The PLCO lung cancer risk models demonstrate high discrimination and calibration.

Citing Articles

Predictive performance of risk prediction models for lung cancer incidence in Western and Asian countries: a systematic review and meta-analysis.

Juang Y, Ang L, Seow W Sci Rep. 2025; 15(1):4259.

PMID: 40038330 PMC: 11880538. DOI: 10.1038/s41598-024-83875-6.


Uptake and 4-week outcomes of an 'opt-out' smoking cessation referral strategy in a London-based lung cancer screening setting.

Bhamani A, Katsampouris E, Bojang F, Verghese P, Creamer A, Prendecki R BMJ Open Respir Res. 2025; 12(1).

PMID: 39915257 PMC: 11804203. DOI: 10.1136/bmjresp-2024-002337.


Current Evidence for a Lung Cancer Screening Program.

Guerreiro T, Aguiar P, Araujo A Port J Public Health. 2024; 42(2):133-158.

PMID: 39469231 PMC: 11498919. DOI: 10.1159/000538434.


Risk Factors and Preventive Measures for Lung Cancer in the European Union.

Kehrle K, Hetjens M, Hetjens S Epidemiologia (Basel). 2024; 5(3):539-546.

PMID: 39311354 PMC: 11417776. DOI: 10.3390/epidemiologia5030037.


Development of a novel nomogram for predicting delayed methotrexate excretion following high-dose methotrexate in adult patients with hematologic malignancies.

Ikeda D, Isezaki T, Narita K, Yuyama S, Oura M, Uehara A Cancer Chemother Pharmacol. 2024; 94(3):397-406.

PMID: 38902559 DOI: 10.1007/s00280-024-04687-z.


References
1.
Hung R, McKay J, Gaborieau V, Boffetta P, Hashibe M, Zaridze D . A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008; 452(7187):633-7. DOI: 10.1038/nature06885. View

2.
Kondo T, Hori Y, Yatsuya H, Tamakoshi K, Toyoshima H, Nishino Y . Lung cancer mortality and body mass index in a Japanese cohort: findings from the Japan Collaborative Cohort Study (JACC Study). Cancer Causes Control. 2007; 18(2):229-34. DOI: 10.1007/s10552-006-0069-8. View

3.
Tammemagi M, Lam S, McWilliams A, Sin D . Incremental value of pulmonary function and sputum DNA image cytometry in lung cancer risk prediction. Cancer Prev Res (Phila). 2011; 4(4):552-61. DOI: 10.1158/1940-6207.CAPR-10-0183. View

4.
Shacter E, Weitzman S . Chronic inflammation and cancer. Oncology (Williston Park). 2002; 16(2):217-26, 229; discussion 230-2. View

5.
Amos C, Wu X, Broderick P, Gorlov I, Gu J, Eisen T . Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet. 2008; 40(5):616-22. PMC: 2713680. DOI: 10.1038/ng.109. View